Key Highlights
- DataMeds AI (NASDAQ:MEDS) is listed at USD 3.05, which is 392% above its 52-week low of USD 0.62 and 95.8% below its high of USD 73.00.
- DataMeds AI, formerly Wellgistics Health, reported second-quarter revenue of USD 1.779 million, up 14% sequentially but far below USD 7.79 million a year earlier, and completed a 1-for-50 reverse split in May.
- The company raised USD 6.5 million in June, restructured USD 14.5 million of debt and secured 90-day lock-ups covering 1,533,930 shares, about 49% of the total.
- A Dream Bowl meme coin distribution of 50 tokens per share was set for September 9, and the stock slipped 0.65% to USD 3.05 on a market value of USD 9.634 million.
The Latest Verified Updates
No company release dated October 13 was found in company filings and wire releases reviewed, so the most relevant recent updates are summarized here. DataMeds AI, a Tampa-based health IT company that changed its name from Wellgistics Health in July and began trading as MEDS on July 22, uses an AI platform called EinsteinRx and a blockchain contract platform called PharmacyChain. Second-quarter 2026 revenue was USD 1.779 million, up 14% from the first quarter but down from USD 7.79 million a year earlier, with a loss of USD 7.13 per share on about 2.57 million weighted shares. The company has about 2.85 million shares outstanding after a 1-for-50 reverse split in May intended to address Nasdaq delisting risk.
Why Trading Is Heavy and What the Data Says
It raised USD 6.5 million in June and restructured USD 14.5 million of debt toward a preferred equity swap, and holders of 1,533,930 shares entered 90-day lock-ups. The board set September 9 for a distribution of Dream Bowl meme coin tokens at 50 per share and a pending deal with Datavault AI and others would consolidate intellectual property for a Health Lives Here app. The 52-week high of USD 73.00 is about 24 times the USD 3.05 price, simple arithmetic, which reflects the reverse split. Simple arithmetic puts the prior close near USD 3.07, so the day's move is about USD 0.02 a share. The price sits 392% above its 52-week low and 95.8% below its high, which frames how much of the range has already been used. The screen shows volume of 13.956 million shares against a three-month average of 5.822 million, or 2.4 times, and arithmetic on that volume implies traded value of about USD 42.6 million, or 4.4 times the market value. Identical volume figures have appeared on several earlier screens, so treat the field as carried over and rely on the drivers above for why the stock is active.
Risks and What to Watch
Falling revenue, restructured debt, lock-up expiries and a USD 9.634 million market value make dilution and delisting real risks. What to watch next: lock-up expiry, financing and the Datavault transaction. This is information only and not investment advice.
Where Things Stand
Market conditions frame the day: oil traded above USD 100, the big banks report this week and speculative technology names were under pressure. DataMeds AI (NASDAQ:MEDS) is moving with a post-reverse-split stabilization attempt. A drop on a stock this small and this volatile can reverse quickly, so the balance of evidence favors waiting for confirmation from filings and the next session. Direction remains unknown, and the next catalyst is lock-up expiry, financing and the Datavault transaction. Check the underlying filings first, verify the latest filings before acting, and treat the figures as a snapshot.

_11_20_2026_19_30_07_879097.jpg)

_11_20_2026_19_32_49_884922.jpg)


Please wait processing your request...